Marc R. Radke

<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Kevin Lin, Maria I. Harrell, Amit M. Oza et al. · Cancer Discovery · 2018 · 403 citations

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 209 citations · Full text

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

Eve T. Rodler, Priyanka Sharma, William E. Barlow et al. · The Lancet Oncology · 2023 · 92 citations · Full text

Breast Oncology, Medicine, Pharmacology +6

Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley et al. · Cancer Research · 2021 · 82 citations · Full text

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

Yifan Wang, Andrea J. Bernhardy, Joseph Nacson et al. · Nature Communications · 2019 · 60 citations · Full text